Featured Research

from universities, journals, and other organizations

Engineered Protein Effective Against Staphylococcus Aureus Toxin

Date:
May 23, 2007
Source:
University of Illinois at Urbana-Champaign
Summary:
Scientists have developed a treatment for exposure to enterotoxin B, a noxious substance produced by the Staphylococcus aureus bacterium. The research team engineered a protein, which was successfully tested in rabbits, that could one day be used to treat humans exposed to the enterotoxin.

Structure of an SEB molecule (blue) in complex with the variable region (grey with colored loops) of the T-cell receptor protein. Various amino acid residues in the loops (especially the residues colored red) were mutated to generate a protein that bound SEB with over one million-fold higher binding than the original. Soluble forms of this mutant protein were capable of neutralizing SEB in rabbit models.
Credit: Image courtesy of David M. Kranz

A research team led by the University of Illinois has developed a treatment for exposure to enterotoxin B, a noxious substance produced by the Staphylococcus aureus bacterium. The team engineered a protein, which was successfully tested in rabbits, that could one day be used to treat humans exposed to the enterotoxin.

S. aureus enterotoxin B (SEB) is a common cause of food poisoning, but if it is inhaled or produced during an infection it can elicit a systemic -- and sometimes fatal -- immune response in humans. In purified form, SEB is listed as a potential bioterrorism agent. Other potent S. aureus enterotoxins include the toxic shock syndrome toxin.

These enterotoxins are classed as superantigens because they set off a massive immune response in humans and other animals. They bind to variable regions of T-cell receptors, stimulating a cascade of events, including the systemic release of inflammatory cytokines. In some cases the powerful immune response leads to toxic shock and death.

The research team, led by University of Illinois professor of biochemistry David M. Kranz, included scientists and clinicians from the Boston Biomedical Research Institute and the University of Minnesota Medical School.

The team began by engineering a protein with the same structure as the binding site of the T-cell receptor targeted by SEB. The researchers expressed the engineered protein on the surface of yeast cells (using a process they helped develop, called "yeast display") and generated mutations meant to increase the protein's ability to bind SEB. After several rounds of mutagenesis and screening, graduate student Rebecca A. Buonpane developed a soluble protein with an affinity for SEB that was over a million times that of the original.

"Our approach was to take these receptors that bind to the toxins and to try to make them higher affinity and therefore act as effective neutralizing agents when delivered in soluble form," Kranz said. "It's the binding of the toxin to T-cells that is critical. If you can prevent the toxin from binding to the T-cell receptor then you can prevent it from initiating that cascade."

The engineered protein prevented the onset of symptoms in rabbits exposed to SEB and reversed the course of the illness in those treated two hours after exposure. "We were very pleasantly surprised that it showed effectiveness in every rabbit tested," Kranz said.

He noted that the protein has some potential advantages and disadvantages when compared to antibodies, which might also be used to fight infection with SEB. One advantage is that the engineered protein is small, about one-tenth the size of an antibody. Its size may allow it to penetrate deeper into tissues, and may make it less likely to spark an immune response in animals. The protein can also be produced in large quantities using the bacterium, Escherichia coli.

"E. coli is the cheapest source for making proteins," Kranz said. "Whenever you can express a protein in E. coli you do so because it is inexpensive, easy and fast."

Antibodies, on the other hand, can remain in the body for days or weeks, whereas the new protein is cleared within hours. This may make antibodies a better treatment option in some circumstances, said Kranz.

No antibody has yet been developed, however, that has a comparable affinity for SEB.

The findings appear in the online edition of Nature Medicine. These studies were supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of Illinois at Urbana-Champaign. Note: Materials may be edited for content and length.


Cite This Page:

University of Illinois at Urbana-Champaign. "Engineered Protein Effective Against Staphylococcus Aureus Toxin." ScienceDaily. ScienceDaily, 23 May 2007. <www.sciencedaily.com/releases/2007/05/070521145512.htm>.
University of Illinois at Urbana-Champaign. (2007, May 23). Engineered Protein Effective Against Staphylococcus Aureus Toxin. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2007/05/070521145512.htm
University of Illinois at Urbana-Champaign. "Engineered Protein Effective Against Staphylococcus Aureus Toxin." ScienceDaily. www.sciencedaily.com/releases/2007/05/070521145512.htm (accessed September 2, 2014).

Share This




More Plants & Animals News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Washington Wildlife Center Goes Nuts Over Baby Squirrels

Washington Wildlife Center Goes Nuts Over Baby Squirrels

Reuters - US Online Video (Aug. 30, 2014) An animal rescue in Washington state receives an influx of orphaned squirrels, keeping workers busy as they nurse them back to health. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Experimental Ebola Drug ZMapp Cures Lab Monkeys Of Disease

Experimental Ebola Drug ZMapp Cures Lab Monkeys Of Disease

Newsy (Aug. 29, 2014) In a new study, a promising experimental treatment for Ebola managed to cure a group of infected macaque monkeys. Video provided by Newsy
Powered by NewsLook.com
Killer Amoeba Found in Louisiana Water System

Killer Amoeba Found in Louisiana Water System

AP (Aug. 28, 2014) State health officials say testing has confirmed the presence of a killer amoeba in a water system serving three St. John the Baptist Parish towns. (Aug. 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins